R1 RCM — Q3 2021 Earnings Presentation
11 slides from R1 RCM's earnings presentation, Nov 2, 2021
Slide 1: Third Quarter 2021 Results Conference Call
Third Quarter 2021 Results Conference Call November 2, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
2 Forward‐Looking Statements and Non‐GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward‐looking statements relate to future, not
Slide 3: Q3 Financial Highlights and Updated 2021 Adjusted EBITDA Guidance
3 Q3 Financial Highlights and Updated 2021 Adjusted EBITDA Guidance Third Quarter 2021 Results Revenue of $379.7 million, up $72.5 million or 23.6% compared to the same period last year GAAP net income of $17.0 million, up $11.8 million or 226.9% compared to the same period last year Adjusted
Slide 4: Q3 Commercial Update
4 Q3 Commercial Update Commercial Update End‐to‐end pipeline has grown by ~50% since Q2 2021; tighter labor market conditions are driving increased interest In contracting stage with prospective customers for end‐to‐end agreements; expect to exceed $4 billion NPR target if contracts are signed b
Slide 5: Q3 Deployment and Technology Update
5 Q3 Deployment and Technology Update Deployment Update LifePoint Phase 1 onboarding scheduled to be completed by end of November Phase 2 onboarding scheduled to be completed in early 2022 Phase 3 onboarding >50% complete, on track for completion by mid‐2022 Mednax Progressing on schedul
Slide 6: 3Q'21 Non-GAAP Results – Q/Q and Y/Y Comparison
6 3Q'21 Non‐GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 3Q'21 2Q'21 3Q'20 Key Change Driver(s) Revenue $379.7 $353.4 $307.2 Q/Q: Continued recovery in patient volumes and higher incentive fees Y/Y: Recovery in patient volumes, new customers onboarded in the last twelve months, and the
Slide 7: Additional Commentary: Strong Balance Sheet and Liquidity Provides Flexibility
7 Additional Commentary Organic and inorganic investments ‐ Approximately $25 million cash from balance sheet to fund VisitPay acquisition and transaction expenses Debt paydown ‐ Repaid $20 million of revolver in Q3 ‐ Net debt1 of $640.8 million as of 9/30/21 Opportunistic share repurchases ‐
Slide 8: Appendix: Reconciliation of GAAP to Non-GAAP Financials
8 Appendix Reconciliation of GAAP to Non‐GAAP Financials
Slide 9: Use of Non-GAAP Financial Measures
9 Use of Non‐GAAP Financial Measures In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non‐GAAP financial measures, inc
Slide 10: Reconciliation of GAAP to Non-GAAP Financials
10 Reconciliation of GAAP to Non‐GAAP Financials Note1: Other expenses are comprised of reorganization‐related costs, strategic initiatives costs, and certain other costs. Three Months Ended September 30, Three Months Ended June 30, 2021 2020 2021 Cost of services $ 304.0 $ 255.2 $ 287.0 Less: Share
Slide 11: Reconciliation of GAAP to Non-GAAP Financials
11 Reconciliation of GAAP to Non‐GAAP Financials Reconciliation of GAAP Operating Income Guidance to Non‐GAAP Adjusted EBITDA Guidance 2021 GAAP Operating Income Guidance $142‐148 Plus: Depreciation and amortization expense $75‐85 Share‐based compensation expense $75‐85 Strategic initiatives, severa